Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:VCEL
- CUSIP: N/A
- Web: www.aastrom.com
Capitalization:- Market Cap: $162.48 million
- Outstanding Shares: 32,824,000
Average Prices:- 50 Day Moving Avg: $3.81
- 200 Day Moving Avg: $3.11
- 52 Week Range: $2.00 - $5.25
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.38
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $53.77 million
- Price / Sales: 3.02
- Book Value: $0.43 per share
- Price / Book: 11.51
Profitability:- EBIDTA: ($20,030,000.00)
- Net Margins: -50.27%
- Return on Assets: -59.46%
Debt:- Debt-to-Equity Ratio: 0.58%
- Current Ratio: 2.55%
- Quick Ratio: 2.31%
Misc:- Average Volume: 519,542 shs.
- Beta: 3.07
- Short Ratio: 5.26
Frequently Asked Questions for Vericel Corporation (NASDAQ:VCEL)
What is Vericel Corporation's stock symbol?
Vericel Corporation trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel Corporation's earnings last quarter?
Vericel Corporation (NASDAQ:VCEL) issued its earnings results on Wednesday, August, 9th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.16. The firm earned $16.95 million during the quarter. View Vericel Corporation's Earnings History.
When will Vericel Corporation make its next earnings announcement?
Where is Vericel Corporation's stock going? Where will Vericel Corporation's stock price be in 2017?
3 brokers have issued 12-month price objectives for Vericel Corporation's stock. Their forecasts range from $6.00 to $7.00. On average, they anticipate Vericel Corporation's stock price to reach $6.33 in the next twelve months. View Analyst Ratings for Vericel Corporation.
Who are some of Vericel Corporation's key competitors?
Some companies that are related to Vericel Corporation include Mirna Therapeutics (SYBX), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), VIVUS (VVUS), Alimera Sciences (ALIM), Cardiome Pharma Corporation (CRME), Opiant Pharmaceuticals (OPNT), KalVista Pharmaceuticals (KALV), Chiasma (CHMA), Tokai Pharmaceuticals (NVUS), Cesca Therapeutics (KOOL) and Ocera Therapeutics (OCRX).
Who are Vericel Corporation's key executives?
Vericel Corporation's management team includes the folowing people:
- Robert L. Zerbe M.D., Independent Chairman of the Board
- Dominick C. Colangelo, President, Chief Executive Officer, Director
- Gerard J. Michel, Chief Financial Officer, Vice President - Corporate Development
- Daniel R. Orlando, Chief Operating Officer, Chief Commercial Officer
- Ross Tubo, Chief Scientific Officer
- David Recker M.D., Chief Medical Officer
- Steven C. Gilman Ph.D., Director
- Heidi Hagen, Director
- Kevin F. McLaughlin, Director
- Paul Kevin Wotton Ph.D., Director
Who owns Vericel Corporation stock?
Vericel Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.10%), Archon Capital Management LLC (4.08%), Vanguard Group Inc. (3.70%), First Washington CORP (2.06%), Perkins Capital Management Inc. (0.79%) and Northern Trust Corp (0.19%). View Institutional Ownership Trends for Vericel Corporation.
Who sold Vericel Corporation stock? Who is selling Vericel Corporation stock?
Who bought Vericel Corporation stock? Who is buying Vericel Corporation stock?
Vericel Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, First Washington CORP, Vanguard Group Inc., Perkins Capital Management Inc., Bank of New York Mellon Corp and Northern Trust Corp. View Insider Buying and Selling for Vericel Corporation.
How do I buy Vericel Corporation stock?
Shares of Vericel Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel Corporation's stock price today?
One share of Vericel Corporation stock can currently be purchased for approximately $4.95.
MarketBeat Community Rating for Vericel Corporation (NASDAQ VCEL)MarketBeat's community ratings are surveys of what our community members think about Vericel Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Vericel Corporation (NASDAQ:VCEL)Earnings History by Quarter for Vericel Corporation (NASDAQ VCEL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.16) | | | | | N/A |  |
| 8/9/2017 | Q2 2017 | ($0.24) | ($0.08) | | $16.95 million | View | Listen | |
| 5/10/2017 | Q1 2017 | ($0.19) | ($0.31) | | $9.36 million | View | N/A | |
| 11/7/2016 | Q3 | ($0.28) | ($0.38) | | $10.93 million | View | Listen | |
| 5/10/2016 | Q116 | ($0.25) | ($0.08) | $11.60 million | $14.10 million | View | Listen | |
| 3/14/2016 | Q415 | ($0.15) | ($0.28) | $17.36 million | $15.40 million | View | Listen | |
| 11/13/2015 | Q315 | ($0.21) | ($0.26) | $10.50 million | $11.30 million | View | Listen | |
| 8/12/2015 | Q215 | ($0.13) | ($0.16) | $11.31 million | $13.60 million | View | Listen | |
| 5/14/2015 | Q115 | ($0.14) | ($0.27) | $11.10 million | $10.80 million | View | Listen | |
| 3/23/2015 | Q414 | ($0.47) | ($0.17) | $10.70 million | $14.70 million | View | Listen | |
| 11/13/2014 | Q314 | ($0.66) | ($0.52) | $6.73 million | $9.66 million | View | N/A | |
| 8/14/2014 | Q214 | ($1.59) | ($0.94) | $2.50 million | $4.43 million | View | N/A | |
| 5/15/2014 | Q114 | ($0.92) | ($1.26) | | | View | N/A | |
| 3/13/2014 | Q413 | ($1.34) | ($0.97) | $0.02 million | $0.01 million | View | N/A | |
| 11/12/2013 | Q3 | ($2.02) | ($0.06) | | | View | Listen | |
| 5/8/2013 | Q1 2013 | ($0.19) | ($0.15) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Vericel Corporation (NASDAQ:VCEL)Current Year EPS Consensus Estimate: $-0.63 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS
Dividend History for Vericel Corporation (NASDAQ:VCEL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vericel Corporation (NASDAQ:VCEL)Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 33.84%
Insider Trades by Quarter for Vericel Corporation (NASDAQ:VCEL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/28/2016 | Consonance Capital Management | Major Shareholder | Sell | 120,000 | $5.39 | $646,800.00 | |
| 9/16/2014 | Daniel Orlando | COO | Buy | 9,804 | $2.55 | $25,000.20 | |
| 9/16/2014 | Dominick Colangelo | CEO | Buy | 20,000 | $2.55 | $51,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Vericel Corporation (NASDAQ:VCEL)
Latest Headlines for Vericel Corporation (NASDAQ:VCEL)
| Source: |
|
| Date | Headline |
|---|
 | Vericel to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 10:48 AM |
 | Vericel Corporation (VCEL) & its Peers Financial Comparison
www.americanbankingnews.com - September 11 at 1:06 PM |
| Vericel Corporation (VCEL) Receives "Buy" Rating from BTIG Research
www.americanbankingnews.com - September 7 at 10:34 AM |
| Vericel Corporation (VCEL) Expected to Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - August 11 at 2:36 PM |
 | Vericel's (VCEL) CEO Nick Colangelo on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 9:19 AM |
| Edited Transcript of VCEL earnings conference call or presentation 9-Aug-17 12:00pm GMT
finance.yahoo.com - August 10 at 9:19 AM |
| Vericel Corporation (NASDAQ:VCEL) Announces Earnings Results
www.americanbankingnews.com - August 9 at 3:03 PM |
| Vericel Reports Second-Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 8:54 AM |
| Vericel Corporation (NASDAQ:VCEL) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:10 AM |
 | Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017 - GlobeNewswire (press release)
globenewswire.com - July 26 at 9:38 AM |
| Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017 - GlobeNewswire (press release)
globenewswire.com - July 26 at 9:38 AM |
| Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017
finance.yahoo.com - July 26 at 9:38 AM |
| Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017
finance.yahoo.com - July 26 at 9:38 AM |
| Vericel Corporation (NASDAQ:VCEL) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - July 22 at 12:08 AM |
 | Vericel to Host Symposium on MACI Implant for Treating Articular ... - Nasdaq
www.nasdaq.com - July 13 at 11:06 AM |
| Vericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting
finance.yahoo.com - July 13 at 11:06 AM |
| ETFs with exposure to Vericel Corp. : July 7, 2017
finance.yahoo.com - July 8 at 4:01 PM |
| Analyzing Horizon Therapeutics (HPTX) & Vericel Corporation (VCEL)
www.americanbankingnews.com - July 2 at 6:26 PM |
| Zacks: Brokerages Anticipate Vericel Corporation (VCEL) to Announce -$0.24 EPS
www.americanbankingnews.com - June 27 at 8:10 PM |
| ETFs with exposure to Vericel Corp. : June 26, 2017
finance.yahoo.com - June 26 at 8:26 PM |
| Week 26 Breakout Forecast Short-Term Picks To Give You An Edge
seekingalpha.com - June 25 at 7:17 AM |
 | UPDATE: BTIG Starts Vericel Corporation (VCEL) at Buy - StreetInsider.com
www.streetinsider.com - June 22 at 2:30 PM |
| Vericel Corporation (VCEL) Coverage Initiated at BTIG Research
www.americanbankingnews.com - June 20 at 5:30 PM |
| ETFs with exposure to Vericel Corp. : June 16, 2017
finance.yahoo.com - June 17 at 7:02 AM |
| Vericel Corp. :VCEL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 15 at 3:37 AM |
| -$0.24 Earnings Per Share Expected for Vericel Corp (VCEL) This Quarter
www.americanbankingnews.com - June 1 at 6:30 PM |
| Edited Transcript of VCEL earnings conference call or presentation 10-May-17 12:00pm GMT
finance.yahoo.com - May 12 at 3:44 AM |
| Vericel Corp (VCEL) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS
www.americanbankingnews.com - May 11 at 4:26 PM |
| Vericel's (VCEL) CEO Nick Colangelo on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 3:03 AM |
| Vericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia
finance.yahoo.com - May 10 at 10:00 AM |
| Vericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
finance.yahoo.com - May 10 at 10:00 AM |
| Vericel Reports First-Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 10:00 AM |
| Investor Network: Vericel Corporation to Host Earnings Call
finance.yahoo.com - May 10 at 10:00 AM |
| Vericel Corp (VCEL) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - May 8 at 1:12 PM |
| Vericel Corp (VCEL) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 7:04 AM |
| Vericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017
finance.yahoo.com - May 5 at 3:10 AM |
| Vericel Corp (VCEL) Getting Somewhat Negative Press Coverage, Report Shows
www.americanbankingnews.com - April 30 at 9:04 AM |
| Short Interest in Vericel Corp (VCEL) Drops By 4.7%
www.americanbankingnews.com - April 29 at 7:18 PM |
| Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day - GlobeNewswire (press release)
globenewswire.com - April 21 at 8:30 PM |
| Analysts Anticipate Vericel Corp (VCEL) to Post -$0.19 Earnings Per Share
www.americanbankingnews.com - April 17 at 3:06 PM |
| Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
finance.yahoo.com - April 10 at 8:00 PM |
| ETFs with exposure to Vericel Corp. : April 7, 2017
finance.yahoo.com - April 7 at 6:21 PM |
| Vericel to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 8:29 AM |
 | Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association
us.rd.yahoo.com - March 23 at 3:50 PM |
| Vericel Corp’s (VCEL) “Buy” Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - March 17 at 9:29 AM |
 | Vericel Corp (VCEL) Gains Despite Projected Loss
www.baystreet.ca - March 11 at 11:33 PM |
| Vericel's (VCEL) CEO Nick Colangelo on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 11 at 9:58 AM |
| Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - March 10 at 10:08 AM |
| VERICEL CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 10 at 10:08 AM |
| Vericel (VCEL) Presents At Cowen and Company 37th Annual Health Care Conference - Slideshow
seekingalpha.com - March 9 at 4:10 AM |
Vericel Corporation (VCEL) Chart for Thursday, September, 21, 2017
